Targeting Amyloid Oligomers for Alzheimer’s Research

Alzheimer’s disease is one of the most frightening diseases people can face. The deterioration of memory and comprehension and, ultimately death, is a terrifying concept. And little headway has been made in developing a treatment for this disease. But that could be changing.

Biogen is likely on the road to having aducanumab approved as a treatment for Alzheimer’s patients, along with Eisai’s BAN2401, both of which are anti-amyloid antibodies. But another treatment could soon be making waves, Alzheon’s ALZ-801, an oral tablet aimed at on high risk APOE4/4 homozygous patients with early to mild Alzheimer’s disease. ALZ-801 acts through a novel molecular mechanism of action blocking the formation of toxic amyloid oligomer.

More: